
Healthfirst Receives Award for Program at High-Volume Substance Use Facilities Supporting Members' Transition Back to Communities
Many of Healthfirst's members living with substance use disorders face barriers in receiving the outpatient care they need to avoid readmission. In fact, 44% of those admitted to the hospital for substance abuse diagnoses are readmitted within 30 days of discharge, and 50% visit the emergency department. To address these challenges, Healthfirst launched an in-person care model that embeds licensed behavioral health clinicians and certified peer support specialists in the highest-volume substance use treatment facilities in the greater New York City area. These care teams engage with members face-to-face during their inpatient stay and continue working with them after discharge to remove barriers to outpatient care, assess social determinants of health, and help members stay on track with their recovery goals.
'A key element of the Behavioral Health Case Management program's success is connecting with members face-to-face during their inpatient stay, often at one of the most difficult times in their recovery,' said Stella V. Pappas, Vice President, Behavioral Health Services at Healthfirst. 'This in-person engagement is essential to earning our members' trust and creates a foundation for ongoing support which helps ensure members are not navigating their recovery alone. For example, our care managers and peer support specialists can understand the member's individual needs and challenges they may face in their recovery and identify solutions that enable them to continue to receive outpatient care and prevent readmission.'
'At a time when the need for behavioral health care is rising, programs like this show what's possible when innovation is grounded in compassion, accountability, and a deep understanding of our members' needs,' said Pat Wang, President and CEO of Healthfirst. 'At Healthfirst, we know that all healthcare is personal, and it is crucial to meet people where they are in a way that feels authentic to them, which is why this integrated approach to behavioral health case management underpinned by data-driven insights has proven effective in reducing readmissions.'
The CMSA Foundation award highlights Healthfirst's continued leadership in advancing behavioral healthcare and reinforces its commitment to delivering compassionate, coordinated services that improve outcomes and reduce preventable hospitalizations. For more information or to view the full case study, visit here.
About Healthfirst
Healthfirst believes that every New Yorker deserves access to the best available healthcare. As one of New York's highest quality health insurers, we make this a reality for more than 2 million members. Founded more than 30 years ago by the leading hospital systems in downstate New York, Healthfirst established a partnership model that enables hospitals, health systems, and physicians in our network to prioritize health outcomes over profits, placing the needs of our members and community first. Healthfirst serves members in New York City, on Long Island, and in Westchester, Rockland, Sullivan, and Orange counties, offering market-leading products to suit every life stage. Our offerings include Medicaid plans, Medicare Advantage plans, Long-Term Care plans, Qualified Health plans, and Essential Plans. For more information on Healthfirst, please visit healthfirst.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Wire
2 days ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Yahoo
2 days ago
- Yahoo
Why Inspire Medical Systems (INSP) Stock Is Trading Up Today
What Happened? Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 3.3% in the morning session after the stock extended its positive momentum as a recent announcement of a $200 million share repurchase program boosted investor confidence. This buyback program, authorized by the company's board, suggests that management believes the stock is undervalued and is a way to signal their commitment to returning value to shareholders despite the recent operational challenges and revised financial guidance. After the initial pop the shares cooled down to $87.91, up 3.9% from previous close. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. What Is The Market Telling Us Inspire Medical Systems's shares are extremely volatile and have had 31 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 4% on the news that its Board of Directors announced a share buyback program of up to $200 million. Share buyback programs are often a sign that a company's leadership believes its stock is undervalued. This sentiment was echoed by CEO Tim Herbert, who stated, 'we remain confident that our growth prospects are substantial… and that our stock is undervalued.' The plan authorizes the company to repurchase up to 8.6% of its shares. This announcement comes after the stock price declined following its recent second-quarter earnings report, suggesting management views the current price as an attractive investment. Adding to the positive momentum, the broader market also rallied on favorable inflation data, which may have provided an additional tailwind for the stock. Inspire Medical Systems is down 53.5% since the beginning of the year, and at $87.91 per share, it is trading 59.4% below its 52-week high of $216.71 from September 2024. Investors who bought $1,000 worth of Inspire Medical Systems's shares 5 years ago would now be looking at an investment worth $818.72. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos